RANKL inhibition with osteoprotegerin increases bone strength by improving cortical and trabecular bone architecture in ovariectomized rats.
about
Relationship between serum RANKL and RANKL in boneAre osteoclasts needed for the bone anabolic response to parathyroid hormone? A study of intermittent parathyroid hormone with denosumab or alendronate in knock-in mice expressing humanized RANKL.Effect of sequential treatments with alendronate, parathyroid hormone (1-34) and raloxifene on cortical bone mass and strength in ovariectomized rats.A novel in vivo gene transfer technique and in vitro cell based assays for the study of bone loss in musculoskeletal disordersA roadmap to the brittle bones of cystic fibrosis.Osteoclasts are dispensable for hematopoietic progenitor mobilization by granulocyte colony-stimulating factor in mice.The antidepressant bupropion exerts alleviating properties in an ovariectomized osteoporotic rat model.Anti-sclerostin antibody treatment in a rat model of progressive renal osteodystrophy.Osteoprotegerin prevents glucocorticoid-induced osteocyte apoptosis in miceOophorectomy-induced bone loss is attenuated in MAGP1-deficient micePossible antiosteoporotic mechanism of Cicer arietinum extract in ovariectomized ratsRANKL inhibitors induce osteonecrosis of the jaw in mice with periapical disease.MicroRNA-106b inhibits osteoclastogenesis and osteolysis by targeting RANKL in giant cell tumor of bone.Characterization of Regulatory Extracellular Vesicles from Osteoclasts.Commitment to the osteoblast lineage is not required for RANKL gene expression.OPG-Fc but Not Zoledronic Acid Discontinuation Reverses Osteonecrosis of the Jaws (ONJ) in Mice.High- and low-dose OPG-Fc cause osteopetrosis-like changes in infant mice.RANKL inhibition for the management of patients with benign metabolic bone disorders.Comparable outcomes in fracture reduction and bone properties with RANKL inhibition and alendronate treatment in a mouse model of osteogenesis imperfecta.RANKL inhibition with denosumab does not influence 3-year progression of aortic calcification or incidence of adverse cardiovascular events in postmenopausal women with osteoporosis and high cardiovascular risk.Skeletal and extraskeletal actions of denosumab.Advances in osteoimmunology: pathophysiologic concepts and treatment opportunities.Locally limited inhibition of bone resorption and orthodontic relapse by recombinant osteoprotegerin protein.Local delivery of recombinant osteoprotegerin enhances postorthodontic tooth stability.Finite Element Analysis of Denosumab Treatment Effects on Vertebral Strength in Ovariectomized Cynomolgus Monkeys.Influence of Fatigue Loading and Bone Turnover on Bone Strength and Pattern of Experimental Fractures of the Tibia in Mice.High fat diet attenuates hyperglycemia, body composition changes, and bone loss in male streptozotocin-induced type 1 diabetic mice.Adenoviral vector-mediated overexpression of osteoprotegerin accelerates osteointegration of titanium implants in ovariectomized rats.Inhibition of sclerostin by monoclonal antibody increases bone formation, bone mass, and bone strength in aged male rats.Pulsed electromagnetic field stimulates osteoprotegerin and reduces RANKL expression in ovariectomized rats.Effects of Salvia miltiorrhiza extract with supplemental liquefied calcium on osteoporosis in calcium-deficient ovariectomized mice.β‑Ecdysterone promotes autophagy and inhibits apoptosis in osteoporotic rats.IL-3 Differentially Regulates Membrane and Soluble RANKL in Osteoblasts through Metalloproteases and the JAK2/STAT5 Pathway and Improves the RANKL/OPG Ratio in Adult Mice.Analysis of early stage osteonecrosis of the human femoral head and the mechanism of femoral head collapse.Effects of combined treatment with ibandronate and pulsed electromagnetic field on ovariectomy-induced osteoporosis in rats.Bone quality is partially recovered after the discontinuation of RANKL administration in rats by increased bone mass on existing trabeculae: an in vivo micro-CT study.Enhanced immunoprotective effects by anti-IL-17 antibody translates to improved skeletal parameters under estrogen deficiency compared with anti-RANKL and anti-TNF-α antibodies.A Clinical Study Evaluating the Effects of Fluvastatin on Serum Osteoprotegerin Levels in Rheumatoid Arthritis Patients.Effect of osteoporosis treatment agents on the cortical bone osteocyte microenvironment in adult estrogen-deficient, osteopenic rats.
P2860
Q28245828-17321C1C-F13D-4218-B7E5-8B658DA716DCQ34107428-3E50237B-64DE-4B31-8FFB-91478251D66CQ34149279-A536EC60-26B0-44DB-B3E7-F732CC2F384BQ34299772-61183A16-4007-466A-936B-6AB1DCDF882EQ34442832-0C2C6C8E-131C-48D0-A438-7DEB9109F7E2Q35070894-22364411-ABDE-4F63-87A5-F40DAF457DDDQ35080134-02C45206-F49B-4E2D-A6BC-0C5507E7EDE9Q35096719-72A58991-9CEF-41D0-9AA5-23B3A30EB7A4Q35175707-7C763750-510B-4FF1-A5E5-4CC1337853A8Q35631694-C3A2CD66-3C6B-400C-8DFC-7ABBB685C51EQ35670191-AF15CFB0-5C09-4826-8C4A-DF2B8229FE28Q35766784-7317548C-0AF4-49DD-99F5-9DCF65B40823Q36326306-94AB48C1-36A7-4DBE-A5A7-04CACFB79593Q37046045-16D29DA9-FDEE-48D6-8ECA-06A77ABCCFE2Q37176364-497C71C1-A386-4F9F-988E-D2EA44F12480Q37199204-4D82902F-0C53-4D2C-9C05-1A81BA4C4D7CQ37463716-C97C822F-6A54-438E-9205-BF4170C80E72Q37532561-308046D5-93ED-435A-9B4A-8E07081ED77DQ37579579-73D24C74-ED12-4558-B3D0-5876BC25D8D2Q37625447-D03F23DA-A7CD-472F-A2EB-4CFE535A79E1Q38009712-24576648-998B-40B2-A67C-D073F59E938AQ38047183-95F205D6-A39B-4BB6-B39A-BF4793EAC910Q38414010-7E57B90A-3AF4-4A64-BE2A-9A9FAD706C72Q38425187-41856FD7-AA0F-4110-BD7B-7E08E006F75AQ39791628-55E2761A-D270-48EB-9F35-9035E8962A54Q39945856-DBFFFC68-DA59-4924-BE11-84005F0C541FQ40165526-06C7E1D4-69B6-4F0D-BA86-90C147B66496Q42148836-C6F67136-51EF-4ED7-9AAB-FCED76CDE53AQ42966206-49B67BD3-CE0A-454D-93C7-E1246E94F5C7Q45899252-2A115849-5BF0-4732-9904-1B21B2EBA024Q47138639-59FE6A0F-4B0E-4F88-A5CF-EF7E6D9A61AEQ47401384-9C42709E-42A3-4FFF-8AE0-296AA1A7DD64Q48184294-AFEF4020-D87B-478A-BB94-F1BDE4263FE7Q50285287-310B2311-5517-4923-8024-DA92B4DDC08AQ51423055-5EADD62F-BAA8-404E-AEDE-63078D944D18Q51565203-7EB300E8-AD22-4AE5-B5CD-103F657CB33BQ53060269-13C123B2-D25C-4A11-A87F-705F8D358A03Q53771696-0D6790DB-272D-4C9F-B878-FE87E0C3A4D1Q55384465-FB07F38D-86C6-4271-90F7-87E25233A411
P2860
RANKL inhibition with osteoprotegerin increases bone strength by improving cortical and trabecular bone architecture in ovariectomized rats.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
2008年學術文章
@zh
2008年學術文章
@zh-hant
name
RANKL inhibition with osteopro ...... ecture in ovariectomized rats.
@en
RANKL inhibition with osteopro ...... ecture in ovariectomized rats.
@nl
type
label
RANKL inhibition with osteopro ...... ecture in ovariectomized rats.
@en
RANKL inhibition with osteopro ...... ecture in ovariectomized rats.
@nl
prefLabel
RANKL inhibition with osteopro ...... ecture in ovariectomized rats.
@en
RANKL inhibition with osteopro ...... ecture in ovariectomized rats.
@nl
P2093
P2860
P356
P1476
RANKL inhibition with osteopro ...... ecture in ovariectomized rats.
@en
P2093
Denise Dwyer
Frank J Asuncion
Hong-Lin Tan
James McCabe
Kelly S Warmington
Marina Stolina
Mario Grisanti
Mauricio Barrero
Michael S Ominsky
P2860
P304
P356
10.1359/JBMR.080109
P577
2008-05-01T00:00:00Z